Double‐blind comparison of an oral <i>Escherichia coli</i> preparation and mesalazine in maintaining remission of ulcerative colitis

Kruis, Wolfgang; Schütz, E; Frič, Pavol; Fixa, B; Judmaier, G; Stolte, Manfred

doi:10.1046/j.1365-2036.1997.00225.x

Cited by 698 publications

(385 citation statements)

References 13 publications

Supporting

Mentioning

343

Contrasting

Unclassified

Order By: Relevance

“…Escherichia coli Nissle 1917 (DSM 6601, serotype O6 : K5 : H1), a non-pathogenic faecal isolate (Blum et al, 1995), is the active component of the probiotic MutaflorH, which is used for the treatment of various gastrointestinal disturbances and diseases (Kruis et al, 1997;Lodinova-Zadnikova et al, 1998;Malchow, 1997;Rembacken et al, 1999). The strain was originally isolated by the physician and bacteriologist A. Nissle during World War I from the only healthy soldier of a group with diarrhoea (Nissle, 1925).…”

Section: Introductionmentioning

confidence: 99%

The colicin G, H and X determinants encode microcins M and H47, which might utilize the catecholate siderophore receptors FepA, Cir, Fiu and IroN

et al. 2003

View full text Add to dashboard Cite

The colicin G producer Escherichia coli CA46, the colicin H producer E. coli CA58 and E. coli Nissle 1917 (DSM 6601) were shown to produce microcin H47 and the newly described microcin M. Both microcins were exported like colicin V by an RND-type export system, including TolC. The gene cluster encoding microcins H47 and M in strains CA46 and CA58 is nearly identical to that in strain DSM 6601, except that two additional genes are included. A Fur box identified in front of the microcin-encoding genes explained the observed iron regulation of microcin production. The catecholate siderophore receptors Fiu, Cir and FepA from E. coli and IroN, Cir and FepA from Salmonella were identified as receptors for microcins M, H47 and E492. IroN takes up the glucose-containing catecholate siderophore salmochelin, whose synthesis is encoded in the iro gene cluster found in Salmonella and certain, often uropathogenic, E. coli strains. A gene in this iro cluster, iroB, which encodes a putative glycosyltransferase, was also found in the microcin H47/M and microcin E492 gene clusters. These microcins could aid the producing strain in competing against enterobacteria that utilize catecholate siderophores.

show abstract

Section: Introductionmentioning

confidence: 99%

The colicin G, H and X determinants encode microcins M and H47, which might utilize the catecholate siderophore receptors FepA, Cir, Fiu and IroN

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Moreover, a commercial consortium of E. coli is believed to result in beneficial effects for premature infants (13). Other E. coli preparations, administered orally, have been used in adults as an option for maintenance therapy of ulcerative colitis (14) or immunomodulation (13,15).…”

Section: Introductionmentioning

confidence: 99%

Effect of the Escherichia coli EMO strain on experimental infection by Salmonella enterica serovar Typhimurium in gnotobiotic mice

Lima‐Filho

Vieira

Arantes

et al. 2004

Braz J Med Biol Res

View full text Add to dashboard Cite

An experimental infection with Salmonella enterica subsp. enterica serovar Typhimurium was evaluated in gnotobiotic mice previously exposed to a plasmid-free non-pathogenic Escherichia coli (EMO strain). Mice were exposed to EMO (experimental) or not (control) 10 days before challenge with Salmonella Typhimurium (10² colony forming units (CFU)/mouse). Survival after challenge was higher (P < 0.05) in the experimental group (16%) than in the control animals (0%). Histopathological examination of the colon and ileum mucosa of the experimental group showed less extensive lesions such as edema, cell inflammatory infiltration and hyperemia. The epithelial cells of the mucosal surface and the production of the mucous layer were also better preserved in the experimental group. The population levels of Salmonella Typhimurium in the feces were initially 10-fold lower (P < 0.05) in the experimental groups. However, 3 days after challenge both experimental and control groups showed similar population levels ranging from 10(8) to()10(9) CFU/g of feces. The intestinal contents of total and anti-Salmonella Typhimurium sIgA were higher in the experimental groups 10 days after inoculation of E. coli EMO strain. Translocation of Salmonella Typhimurium to the spleen was 10-fold lower (P < 0.05) in the experimental group only on day 3 after infection. This was not related to an increase in the bacterial blood clearance of the animals, as shown by experimental venous challenge with E. coli B41. In conclusion, treatment of mice with E. coli EMO strain promoted a relative protection against experimental infection with Salmonella Typhimurium. This protection was not due to the reduction of the population of pathogens in the intestine but was probably related to stimulation of the immune response

show abstract

“…or nonpathogenic E. coli significantly reduce the severity of spontaneous or chemically induced colitis in animals and is effective in the maintenance treatment of patients with UC or chronic relapsing pouchitis. 26,27,28 In addition, bacteria can be genetically manipulated either to express surface proteins or to release cytokines to modulate the activity of the mucosal immune system. Thus, E. coli, Salmonella and Shigella spp.…”

Section: Discussionmentioning

confidence: 99%

Engineered E. coli delivers therapeutic genes to the colonic mucosa

et al. 2005

View full text Add to dashboard Cite

Taking advantage of the proximity of bowel mucosa to luminal bacteria, we have attempetd to deliver a therapeutic gene to the colonic mucosa by oral administration of an invasive and non-pathogenic Escherichia coli. E. coli diamenopimelate (dap) auxotroph, harboring plasmid pGB2Oinv-hly, express the inv gene from Yersinia pseudotubercolosis that confers the ability to invade nonprofessional phagocytic cells and the hly gene from Listeria monocytogenes that allows expression of lystreriolysin O, a perforin cytolysin able to perfore phagosomal membranes. This bacterial vector invades and transfers functional DNA to epithelial cells in vitro. We have shown that this strain carrying a therapeutic gene (pC1OTGF-b1) can significantly reduce the severity of experimental colitis in mice. However, as a consequence of mucosal barrier disruption during colitis, vector-specific mRNA transcripts could be recovered from the colon and also from extra-colonic tissues. We therefore replaced the constitutive CMV promoter in pC1OTGF-b1 by the inflammation-inducible interleukin-8 promoter generating plasmid pC1OTGF-b1 IND . Plasmid-specific TGF-b1 mRNA transcripts were detectable in mouse CMT-93 epithelial cells incubated with E. coli BM2710/pGB2Oinv-hly carrying pC1OTGF-b1 IND following exposure to inflammatory cytokines. Furthermore, the transcripts were detectable only within inflamed tissues and the therapeutic effects were comparable to those in animals treated with E. coli BM2710/ pGB2Oinv-hly+pC1OTGF-b1. In summary, engineered enteric bacteria can efficiently deliver in vivo therapeutic genes to the intact intestinal mucosa and regulation expression of the therapeutic gene by an inflammation-inducible promoter prevents its dissemination during colitis.

show abstract

Double‐blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis

Cited by 698 publications

References 13 publications

The colicin G, H and X determinants encode microcins M and H47, which might utilize the catecholate siderophore receptors FepA, Cir, Fiu and IroN

The colicin G, H and X determinants encode microcins M and H47, which might utilize the catecholate siderophore receptors FepA, Cir, Fiu and IroN

Effect of the Escherichia coli EMO strain on experimental infection by Salmonella enterica serovar Typhimurium in gnotobiotic mice

Engineered E. coli delivers therapeutic genes to the colonic mucosa

Contact Info

Product

Resources

About